Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.

Dettagli Bibliografici
Autori principali:	Croucher, P, Hijzen, A, Shipman, C, Perry, M, Lippitt, J, Green, J, Van Camp, B, Vanderkerken, K
Natura:	Journal article
Pubblicazione:	2001

Documenti analoghi

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
di: Croucher, P, et al.
Pubblicazione: (2002)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
di: Shipman, C, et al.
Pubblicazione: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
di: Croucher, P, et al.
Pubblicazione: (2001)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
di: Croucher, P, et al.
Pubblicazione: (2001)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
di: Croucher, P, et al.
Pubblicazione: (2003)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
di: Croucher, P, et al.
Pubblicazione: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
di: Croucher, P, et al.
Pubblicazione: (2003)

Osteoprotegerin and the development of myeloma bone disease
di: Croucher, P, et al.
Pubblicazione: (2004)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
di: Shipman, C, et al.
Pubblicazione: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
di: Shipman, C, et al.
Pubblicazione: (2002)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
di: Vanderkerken, K, et al.
Pubblicazione: (2003)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
di: De Leenheer, E, et al.
Pubblicazione: (2004)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
di: De Leenheer, E, et al.
Pubblicazione: (2002)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
di: Croucher, P, et al.
Pubblicazione: (2002)

Bisphosphonates and in vivo models of multiple myeloma - Reply
di: Shipman, C, et al.
Pubblicazione: (2001)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
di: Shipman, C, et al.
Pubblicazione: (2000)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
di: Huan Liu, et al.
Pubblicazione: (2022-06-01)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
di: Dongzheng Gai, et al.
Pubblicazione: (2022-09-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
di: Dirk Hose, et al.
Pubblicazione: (2024-12-01)

Bisphosphonates--mechanisms of action in multiple myeloma.
di: Shipman, C, et al.
Pubblicazione: (2000)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
di: Lwin, S, et al.
Pubblicazione: (2017)

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
di: Dirk Hose, et al.
Pubblicazione: (2025-01-01)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
di: Shipman, C, et al.
Pubblicazione: (2000)

Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases.
di: Ersek, A, et al.
Pubblicazione: (2012)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
di: Mueller, G, et al.
Pubblicazione: (2004)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
di: Dongyeop Shin, et al.
Pubblicazione: (2024-01-01)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
di: Mueller, G, et al.
Pubblicazione: (2004)

Advances in the management of myeloma bone disease.
di: Shipman, C, et al.
Pubblicazione: (2005)

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma
di: Fumou Sun, et al.
Pubblicazione: (2020-03-01)

LONG-ACTING ZOLEDRONIC ACID: ONCE-YEARLY ADMINISTRATION AND EFFICACY EVALUATION IN MYELOMA BONE DISEASE
di: Murat Çınarsoy
Pubblicazione: (2024-12-01)

Osteolytic lesions: Multiple myeloma or prostate cancer?
di: Akshitha Devaraj, MBBS, et al.
Pubblicazione: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
di: Aiken Dao, et al.
Pubblicazione: (2022-12-01)

Tumor-host cell interactions in the bone disease of myeloma.
di: Fowler, J, et al.
Pubblicazione: (2011)

Promotion of Bone Lesions Through the Myeloma Integrin α6-Mediated Osteolytic Signaling
di: Huan Liu, et al.
Pubblicazione: (2021-06-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
di: Clive Henry Buckle, et al.
Pubblicazione: (2012-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
di: Jagdev, S, et al.
Pubblicazione: (2001)

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
di: Rui Liu, et al.
Pubblicazione: (2025-01-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
di: Domingos Sousa, et al.
Pubblicazione: (2020-11-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
di: Shipman, C, et al.
Pubblicazione: (2003)

Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis
di: Salvatore J. Coniglio
Pubblicazione: (2018-06-01)